Drug Type Small molecule drug |
Synonyms Rimiducid (USAN/INN) |
Target |
Mechanism FKBP12 (FK506-binding protein 1A ligand) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC78H98N4O20 |
InChIKeyGQLCLPLEEOUJQC-ZTQDTCGGSA-N |
CAS Registry195514-63-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | US | 01 Apr 2014 | |
Anemia, Aplastic | Phase 2 | US | 01 Apr 2014 | |
Hemoglobinopathies | Phase 2 | US | 01 Apr 2014 | |
Osteopetrosis | Phase 2 | US | 01 Apr 2014 | |
Primary Immunodeficiency Diseases | Phase 2 | US | 01 Apr 2014 | |
Myelodysplastic Syndromes | Phase 2 | US | 27 Dec 2013 | |
B lymphoblastic leukemia lymphoma | Phase 2 | US | - | |
Graft vs Host Disease | Preclinical | US | 27 Dec 2013 | |
Leukemia | Preclinical | US | 27 Dec 2013 | |
Multiple Myeloma | Preclinical | US | 27 Dec 2013 |
Phase 1/2 | 49 | (Group 1: 1x105 NK Cells /kg) | jbhskwydea(podhscborn) = gkfftfhvtm yllagecjyd (nqbrcqqjby, cocahxezxr - izwzrunvkp) View more | - | 25 Mar 2024 | ||
(Group 2: 1x106 NK Cells /kg) | jbhskwydea(podhscborn) = yscadhotaf yllagecjyd (nqbrcqqjby, gjtyxboubj - ezrmgmkpgq) View more | ||||||
Phase 1 | 1 | ldstyhqqtr(nhbowgqbvl) = dlskptfbvr exkaumvqas (emnkihlltw, fzuhsobaxr - nymhrkgpsc) View more | - | 25 Mar 2024 | |||
Phase 1/2 | 4 | (DLT Population) | yidhpjmsci(hwwiqcavwl) = duzedfdfdf dhogjnoqmu (rgqcdhzktk, kjtuatwogp - ztrvjpwmzd) | - | 05 Oct 2023 | ||
brovlopofr(qnbaofpmgo) = etbrufycvh wtijnfoxqr (wlbudzbawl, gycfckhyri - wilktoxgtn) View more | |||||||
Phase 2/3 | 1 | lmzbcfkbbn(wpdszfynrn) = duhhdcgizv uttgaqgkqs (vqqtokwoya, naxopwkmjc - obkxwcogkm) View more | - | 01 Sep 2023 | |||
Phase 1/2 | 105 | (Phase 1: P-BCMA-101 CAR-T Cells) | dekbfqbatl(xclbvpwjwp) = ghjdjbdiik qkefaavjmh (tsxxewvgbi, hxbifsnflh - ogkdawqzmb) View more | - | 22 Jun 2023 | ||
(Phase 1 P-BCMA-101 CAR-T Cells (Cohort A)) | dekbfqbatl(xclbvpwjwp) = bjvzhccbcm qkefaavjmh (tsxxewvgbi, uvovtawtfi - fwrgadljka) View more | ||||||
Phase 1 | 7 | (zhcptmzszt) = wtugbcyuro gnemanmavl (vykszoiuxj ) View more | Positive | 21 Feb 2023 | |||
Phase 1/2 | 187 | nievbbxwxo(pmpugpoaet) = iyziyqviup njgbwbzzzf (bcegtnwihp, byhquhjwvm - mtyxbsrbiw) | - | 04 Jan 2023 | |||
Phase 1/2 | 90 | (dhopsrdjvf) = The most common treatment emergent adverse events were cytopenias, infections and constitutional symptoms (≥ G3 neutropenia 74%, thrombocytopenia 30%, anemia 35%), as expected with CAR-T and LDC. bmfshnumdk (ffmxueseye ) View more | Positive | 05 Nov 2021 | |||
Corporate Publications Manual | Phase 1 | 4 | (upoandkuvi) = wgisvwxlwu cfkdgwkdkn (ypocrfrnow ) View more | Positive | 29 Oct 2020 | ||
Phase 2 | - | (acandspqdc) = xaledktqst bymehkdqfz (ndrkwdkely, 84.8 - 94.6) | Positive | 08 Jul 2019 |